NYKODE-THERAPEUTICS
23.11.2021 07:02:07 CET | Business Wire | Press release
Nykode Therapeutics (formerly Vaccibody*) ) (Euronext Growth (Oslo): VACC (ticker will soon be changed)), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, announced today that the Company is changing its name to reflect its exciting development and mark a milestone in our journey of growth and transformation. It acts as a visible symbol of a new phase of opportunity based on collaborations, internationalization, and future ambitions. And it conveys how we are truly starting to realize our vision of being a leading immunotherapy platform company, breaking down the boundaries of conventional drug design to unlock the future of medicine.
The Company’s new name is inspired by its Norwegian roots and links to our platform’s modularity. Nykode translates as ‘new code’, playing on the potential of our technology to generate novel codes and create innovative patient therapies.
Michael Engsig, CEO of Nykode Therapeutics: “Over the last few years, the Company has made significant steps forward. We have reported promising clinical data, continued to grow our pipeline and forged significant partnerships.” Michael Engsig added, “We continue our exciting transformation from a two-asset focused company to a fully-fledged platform biotech company. During the past year, we have increased the number of talented colleagues, made important additions to our senior management team, invested strategically, and expanded internationally. This positive evolution, combined with our future ambitions, inspired the need to revisit our brand.”
Agnete B. Fredriksen, Chief Innovation & Strategy Officer of Nykode Therapeutics, continued, “The challenge of changing our name was to consolidate everything we have achieved to date with our future plans to expand, and combine this into a powerful new brand.” Agnete B. Fredriksen added, “We have shown that we can generate novel molecules by combining multiple different genes or codes to generate new medicines with unique properties. We will build further on this know-how, driven by our guiding purpose to push the boundaries of human advancement by rethinking conventional drug design. We want to express how our platform’s intelligent modular design and tailored hyper targeting may deliver game-changing medicines for patients. This vision aims to create innovative therapies and continues to broaden our reach into multiple therapeutic areas, both with and without our partners. In essence, we believe that our new name, Nykode, uniquely captures our progress and possibilities.”
Read more about the journey and inspiration regarding our new name, logo, and visual identity on our new website, nykode.com.
*) Vaccibody AS, which is changing its company name to Nykode Therapeutics AS, has called for an EGM on November 30, 2021, to vote for the approval of the change of its company name from Vaccibody AS to Nykode Therapeutics AS.
About Nykode Therapeutics
Nykode Therapeutics, is a clinical-stage biopharmaceutical company, dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment cancer and infectious diseases. Nykode Therapeutics’ modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which are essential for inducing rapid, strong and long-lasting antigen specific immune responses and elicit efficacious clinical responses.
Its lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which is in Phase 2 for the treatment of cervical cancer; and VB10.NEO, a cancer neoantigen vaccine, which is exclusively out licensed to Genentech and is in Phase 1b for the treatment of locally advanced and metastatic tumours and Phase 1/2a for the treatment of melanoma, lung-, head and neck, renal-, and bladder cancer. Additionally, Nykode Therapeutics has initiated a Phase 1/2 trial in 2021 with its two next-generation COVID-19 vaccine candidates.
The Company has collaborations with Roche, Genentech and Nektar Therapeutics within oncology, a multi-target collaboration with Regeneron within oncology and infectious diseases and collaborate with Adaptive Biotechnologies for COVID-19 T cell vaccine development.
Nykode Therapeutics’ shares are traded on Euronext Growth (Oslo), a trading platform operated by Euronext, the leading Pan-European market infrastructure. The ticker code is VACC (ticker will soon be changed). Further information about Nykode Therapeutics may be found at http://www.nykode.com
Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006744/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xylem Expands Long-Term Water Partnership with Dow8.6.2026 14:00:00 CEST | Press release
Agreement to design, build and operate advanced water solution Project to advance integrated water reuse capability, significantly reducing freshwater demand Xylem (NYSE: XYL), a leading global water technology company, today announced a landmark agreement with Dow (NYSE: DOW) to design, build and operate advanced water systems at its large-scale industrial complex in Fort Saskatchewan, Alberta, Canada. The agreement expands Xylem’s long-standing collaboration with Dow, supporting the increased operations tied to Dow’s Path2Zero project. Under the agreement, Xylem will deliver a full end-to-end solution that includes engineering, system design, and long-term operation. The project is designed to support reliable, high-quality water supply, treatment, and reuse across the site. The system is expected to be operational by August 2028. “This agreement represents a major milestone for Xylem,” said Rodney Aulick, EVP and President, Water Solutions and Services at Xylem. “It reflects the str
Seequent and Cascade Institute Partner to Map Canada’s Deep Geothermal Resources8.6.2026 14:00:00 CEST | Press release
State-of-the-art thermal model will provide a nationwide view of subsurface heat to accelerate Canada’s clean energy goals Seequent, The Bentley Subsurface Company, and the Cascade Institute today announced a collaboration to develop a Canadian Thermal Model. This landmark national initiative will reveal Canada’s deep geothermal resources and accelerate the development of renewable energy. The announcement comes on the opening day of the world’s biggest geothermal event, the World Geothermal Congress, being held in Calgary from 8 to 11 June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608741816/en/ The Canadian Thermal Model will integrate over 20 input layers of geoscientific data related to geothermal energy to evaluate Canada’s nationwide deep heat resources. As investment in geothermal energy surges globally as a reliable, always-on clean power source, the Canadian Thermal Model will create a comprehensive national
AdvanCell Strengthens Executive Leadership to Accelerate U.S. Expansion and Scale its Global Targeted Alpha Therapy Platform8.6.2026 14:00:00 CEST | Press release
Justyna Kelly, MSc, joins as Chief Technology Officer and François Gaudet, PhD, joins as Chief Scientific Officer, further building AdvanCell’s U.S. based leadership team Simon Puttick, PhD, transitions to Chief Isotope Development Officer and continues to lead isotope innovation efforts from Australia Appointments reflect AdvanCell’s continued investment in pipeline advancement, global scale-up, manufacturing readiness and isotope capabilities AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Justyna Kelly as Chief Technology Officer (CTO) and François Gaudet as Chief Scientific Officer (CSO), expanding the company’s executive leadership team in the U.S. as it continues to scale its U.S. capabilities, and advance its growing pipeline of innovative targeted alpha therapies. Justyna Kelly will lead AdvanCell’s global technical operations strategy, including CMC, GMP production and clinica
SLB OneSubsea Secures Subsea Boosting Contract for bp’s Thunder Horse Project in Gulf of America8.6.2026 14:00:00 CEST | Press release
Standardized system solution supports efficiency gains and shorter delivery timelines Global energy technology company SLB (NYSE: SLB) today announced that its OneSubsea™ joint venture has been awarded a contract by bp to provide a subsea boosting system for the Thunder Horse project, a development in the deepwater portion of Gulf of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605895157/en/ SLB OneSubsea™ joint venture has been awarded a contract by bp to provide a subsea boosting system for the Thunder Horse project, a development in the deepwater portion of Gulf of America. This engineering, procurement and construction (EPC) contract for Thunder Horse follows recent subsea boosting contract awards for bp’s Kaskida and Tiber developments. All three projects leverage the same supplier-led, standardized subsea boosting system solution, which helps improve execution efficiency and shorten delivery times. As par
AB InBev Turns Bars into Stadiums During Biggest-Ever FIFA World Cup™8.6.2026 14:00:00 CEST | Press release
‘Cheers to Bars’ Global Platform Calls for People to Gather and Celebrate at Bars Everywhere Today, AB InBev, the world’s leading brewer, launched its global “Cheers to Bars” platform – a celebration of local bars and their impact on communities all over the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608956519/en/ Bars have always been more than places to grab a beer. They are where people come together to connect, celebrate milestones, build friendships, and create lasting memories. As hubs of social connection, bars play an important role in strengthening communities and bringing people closer together. “During the FIFA World Cup 2026™, bars will become the beating heart of every neighborhood – places where strangers become friends, every goal is celebrated as one, and collective memories are created with every raised glass,” said Michel Doukeris, CEO, AB InBev. “Beer and football have long been catalysts for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom